发明名称 Compositions and methods for regulating angiogenesis
摘要 In accordance with the present invention, EC progenitors can be used in a method for regulating angiogenesis, i.e., enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g. anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.
申请公布号 US9095580(B2) 申请公布日期 2015.08.04
申请号 US201113301475 申请日期 2011.11.21
申请人 GENESYS RESEARCH INSTITUTION INC. 发明人 Isner Jeffrey M.;Asahara Takayuki;Losordo Douglas W.
分类号 A61K35/28;A61K35/44;A61K45/06;C12N5/071;G01N33/569;A61K35/12 主分类号 A61K35/28
代理机构 Mintz Levin Cohn Ferris Glovsky and Popeo, P. C. 代理人 Mintz Levin Cohn Ferris Glovsky and Popeo, P. C. ;Conlin David G.;Neuner George W.
主权项 1. A method for reducing peripheral vascular trauma during a stent or angioplasty procedure, comprising performing a stent or angioplasty procedure on a patient and administering to the patient, before or after the procedure, a pharmaceutical composition comprising a pharmaceutical carrier and a CD34+, Flk-1+, and tie-2+endothelial cell (EC) progenitor which comprises or is coupled to a cytotoxic agent, a label, a co-stimulatory molecule for stimulating an immune reaction, an angiogenesis inhibitor, a recombinant endothelial cell mitogen or an antitumor drug.
地址 Boston MA US
您可能感兴趣的专利